【渤健中国:渐冻症精准治疗药物托夫生注射液在中国商业上市】6月10日,渤健中国宣布,创新药物托夫生注射液正式在中国商业上市,意味着我国符合条件的渐冻症患者即将有机会用上这款创新药物。作为全球首个获批的肌萎缩侧索硬化精准治疗药物,托夫生注射液于去年9月在中国获批,用于治疗携带超氧化物歧化酶1基因突变的肌萎缩侧索硬化成人患者。

金融界
10 Jun
6月10日,渤健中国宣布,创新药物托夫生注射液正式在中国商业上市,意味着我国符合条件的渐冻症患者即将有机会用上这款创新药物。作为全球首个获批的肌萎缩侧索硬化精准治疗药物,托夫生注射液于去年9月在中国获批,用于治疗携带超氧化物歧化酶1基因突变的肌萎缩侧索硬化成人患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10